Physician profile
David Michael Dspain
NPI 1093918617
$2,441.33
in general payments reported to CMS, 2019-2025
41 companies · $909 in 2025
The $909 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2021: $25.21 · 2022: $81.74 · 2023: $238 · 2024: $641 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752 · Education: $36.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.76 |
| Education | $36.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $267.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $156.43 | 2024-2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $156.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $132.44 | 2024-2025 | Libtayo |
| Incyte Corporation | $113.17 | 2019-2025 | Monjuvi |
| Sirtex Medical INC | $111.89 | 2019 | |
| Array Biopharma INC | $106.19 | 2024-2025 | Xalkori, Lorbrena, Braftovi |
| E.R. Squibb & Sons, L.L.C. | $100.11 | 2024-2025 | Opdivo |
| Celgene Corporation | $97.18 | 2025 | Reblozyl |
| Eisai INC. | $82.99 | 2022-2025 | |
| Janssen Biotech, INC. | $79.79 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Servier Pharmaceuticals LLC | $75.07 | 2024 | |
| Stryker Corporation | $70.39 | 2023 | Optablate |
| Abbvie INC. | $65.45 | 2024-2025 | |
| Puma Biotechnology, INC. | $60.43 | 2019-2023 | Nerlynx |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dspain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.